The global cryptococcosis drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). Cryptococcosis is a fungus caused by Cryptococcus neoformans and Cryptococcus gattii that mostly affects the central nervous system and lungs. People with weaker immune systems, such as those with AIDS, Hodgkin lymphoma, other lymphomas, sarcoidosis, and solid organ transplantation, are more susceptible to this type of infection. Inhalation of dust containing yeast cells is the most common way to contract cryptococcosis, which usually affects the lungs. Fever, malaise, cough, hemoptysis (bloody or blood-tinged sputum), headache, visual abnormalities (blurry or double vision, photophobia), and other symptoms are all signs of cryptococcosis. The diagnosis of cryptococcosis is clinical and microscopic, with culture or fixed-tissue staining confirming the diagnosis. 

Globally, roughly one million cases of cryptococcosis are recorded each year, resulting in around 625,000 fatalities, according to the United Nations Program on HIV/AIDS and the World Health Organization. According to the Centers for Disease Control and Prevention and the World Health Organization, 220,000 instances of cryptococcal meningitis occur each year among HIV/AIDS patients globally, resulting in over 181,000 mortalities. As a result of the rising frequency of cryptococcosis and the availability of advanced therapy, the cryptococcosis disorders market is expected to rise. In the projected years, however, unfavourable effects connected with the usage of medication are likely to hinder the market growth.

Flucytosine is a water-soluble nucleoside analogue antifungal medication that works by inhibiting pyrimidine metabolism in the nucleus of the fungal cell. Flucytosine is commonly used in combination with other antifungal drugs as a first-line treatment. As it is used as a first-line treatment in conjunction with other antifungal drugs, flucytosine was a substantial revenue holding sector. Globally, roughly one million cases of cryptococcosis are recorded each year, resulting in around 625,000 fatalities, according to the United Nations Program on HIV/AIDS and the WHO. The rising prevalence of cryptococcosis, as well as the availability of novel and enhanced treatment options, are driving the cryptococcosis market.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Bristol Myers Squibb Co., Pfizer Inc., Janssen Biotech Inc., Bristol-Myers Squibb Company, and Novartis International AG, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cryptococcosis Drugs Market Report Segmentation

By Treatment 

• Amphotericin B

• Flucytosine

• Fluconazole

• Others

Global Cryptococcosis Drugs Market by Region